Physician profile
Patrick R Carmichael
NPI 1740242007
$9,636.65
in general payments reported to CMS, 2019-2025
42 companies · $920 in 2025
The $920 reported for 2025 was more than what 84% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $804 · 2020: $1,270 · 2021: $1,582 · 2022: $1,877 · 2023: $2,051 · 2024: $1,132 · 2025: $920.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,059 · Education: $43.98.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,059.37 |
| Education | $43.98 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $2,591.42 | 2019-2025 | Ozempic, Wegovy, Rybelsus |
| Lilly USA, LLC | $1,121.00 | 2019-2025 | Mounjaro, Jardiance, Zepbound |
| Astrazeneca Pharmaceuticals Lp | $863.97 | 2019-2023 | Farxiga, Breztri |
| Boehringer Ingelheim Pharmaceuticals, INC. | $808.78 | 2019-2024 | Jardiance |
| Pfizer INC. | $538.32 | 2019-2025 | |
| Amgen INC. | $521.40 | 2019-2025 | Repatha, Otezla, Prolia |
| Abbvie INC. | $445.87 | 2021-2025 | Vraylar, Qulipta, Ubrelvy |
| Abbott Laboratories | $424.75 | 2021-2025 | Freestyle Libre 3, Freestyle Libre 2 |
| Glaxosmithkline, LLC. | $241.22 | 2019-2025 | Arexvy, Shingrix, Trelegy Ellipta |
| Esperion Therapeutics, INC. | $226.06 | 2020-2021 | |
| Amarin Pharma, INC. | $178.34 | 2019-2021 | |
| Eisai INC. | $161.92 | 2020-2025 | |
| Merck Sharp & Dohme LLC | $137.60 | 2019-2024 | Steglatro, Belsomra, Gardasil 9 |
| Exact Sciences Corporation | $128.81 | 2023-2025 | Cologuard Collection Kit |
| Kowa Pharmaceuticals America, INC. | $110.19 | 2019-2021 |
Show all 42 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Patrick Carmichael listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.